Table 2 Open in new tab Relationship...

	Model 1^a	Model 2^b
Full cohort (n = 643)
All-cause mortality
TSH	0.92	0.78–1.09	.32	0.87	0.71–1.07	.19
FT₃	0.81	0.73–0.91	<.001	0.91	0.81–1.01	.08
FT₄	1.09	0.99–1.21	.08	1.07	0.96–1.19	.22
rT₃	1.23	1.12–1.34	<.001	1.18	1.07–1.31	.001
Cardiovascular mortality
TSH	1.03	0.88–1.19	.74	0.96	0.74–1.25	.76
FT₃	0.85	0.74–0.97	.02	0.97	0.84–1.12	.70
FT₄	1.03	0.90–1.17	.71	0.99	0.86–1.15	.93
rT₃	1.22	1.08–1.38	.002	1.13	0.99–1.29	.07
Euthyroid at baseline (n = 534)
All-cause mortality
TSH	0.64	0.43–0.95	.027	0.72	0.47–1.09	.12
FT₃	0.75	0.66–0.84	<.001	0.84	0.74–0.96	.008
FT₄	1.05	0.94–1.18	.40	1.03	0.90–1.17	.69
rT₃	1.22	1.11–1.35	<.001	1.17	1.05–1.31	.006
Cardiovascular mortality
TSH	0.74	0.44–1.24	.26	0.88	0.51–1.52	.65
FT₃	0.78	0.66–0.91	.002	0.90	0.77–1.06	.22
FT₄	1.00	0.86–1.17	.98	0.96	0.81–1.13	.61
rT₃	1.21	1.06–1.38	.006	1.10	0.95–1.28	.20

Model 1^a

Model 2^b

HR^c

95% CI

P-Value

HR^c

95% CI

P-Value

Full cohort (n = 643)

All-cause mortality

TSH

0.92

0.78–1.09

.32

0.87

0.71–1.07

.19

FT₃

0.81

0.73–0.91

<.001

0.91

0.81–1.01

.08

FT₄

1.09

0.99–1.21

.08

1.07

0.96–1.19

.22

rT₃

1.23

1.12–1.34

<.001

1.18

1.07–1.31

.001

Cardiovascular mortality

TSH

1.03

0.88–1.19

.74

0.96

0.74–1.25

.76

FT₃

0.85

0.74–0.97

.02

0.97

0.84–1.12

.70

FT₄

1.03

0.90–1.17

.71

0.99

0.86–1.15

.93

rT₃

1.22

1.08–1.38

.002

1.13

0.99–1.29

.07

Euthyroid at baseline (n = 534)

All-cause mortality

TSH

0.64

0.43–0.95

.027

0.72

0.47–1.09

.12

FT₃

0.75

0.66–0.84

<.001

0.84

0.74–0.96

.008

FT₄

1.05

0.94–1.18

.40

1.03

0.90–1.17

.69

rT₃

1.22

1.11–1.35

<.001

1.17

1.05–1.31

.006

Cardiovascular mortality

TSH

0.74

0.44–1.24

.26

0.88

0.51–1.52

.65

FT₃

0.78

0.66–0.91

.002

0.90

0.77–1.06

.22

FT₄

1.00

0.86–1.17

.98

0.96

0.81–1.13

.61

rT₃

1.21

1.06–1.38

.006

1.10

0.95–1.28

.20

	Model 1^a	Model 2^b
Full cohort (n = 643)
All-cause mortality
TSH	0.92	0.78–1.09	.32	0.87	0.71–1.07	.19
FT₃	0.81	0.73–0.91	<.001	0.91	0.81–1.01	.08
FT₄	1.09	0.99–1.21	.08	1.07	0.96–1.19	.22
rT₃	1.23	1.12–1.34	<.001	1.18	1.07–1.31	.001
Cardiovascular mortality
TSH	1.03	0.88–1.19	.74	0.96	0.74–1.25	.76
FT₃	0.85	0.74–0.97	.02	0.97	0.84–1.12	.70
FT₄	1.03	0.90–1.17	.71	0.99	0.86–1.15	.93
rT₃	1.22	1.08–1.38	.002	1.13	0.99–1.29	.07
Euthyroid at baseline (n = 534)
All-cause mortality
TSH	0.64	0.43–0.95	.027	0.72	0.47–1.09	.12
FT₃	0.75	0.66–0.84	<.001	0.84	0.74–0.96	.008
FT₄	1.05	0.94–1.18	.40	1.03	0.90–1.17	.69
rT₃	1.22	1.11–1.35	<.001	1.17	1.05–1.31	.006
Cardiovascular mortality
TSH	0.74	0.44–1.24	.26	0.88	0.51–1.52	.65
FT₃	0.78	0.66–0.91	.002	0.90	0.77–1.06	.22
FT₄	1.00	0.86–1.17	.98	0.96	0.81–1.13	.61
rT₃	1.21	1.06–1.38	.006	1.10	0.95–1.28	.20

Table 2

Open in new tab

Relationship Between Thyroid Hormones and All-cause and Cardiovascular Mortality in the Full Cohort and in Euthyroid Participants; HRs (per Unit Increase) and 95% CIs

	Model 1^a			Model 2^b
	HR^c	95% CI	P-Value	HR^c	95% CI	P-Value
Full cohort (n = 643)
All-cause mortality
TSH	0.92	0.78–1.09	.32	0.87	0.71–1.07	.19
FT₃	0.81	0.73–0.91	<.001	0.91	0.81–1.01	.08
FT₄	1.09	0.99–1.21	.08	1.07	0.96–1.19	.22
rT₃	1.23	1.12–1.34	<.001	1.18	1.07–1.31	.001
Cardiovascular mortality
TSH	1.03	0.88–1.19	.74	0.96	0.74–1.25	.76
FT₃	0.85	0.74–0.97	.02	0.97	0.84–1.12	.70
FT₄	1.03	0.90–1.17	.71	0.99	0.86–1.15	.93
rT₃	1.22	1.08–1.38	.002	1.13	0.99–1.29	.07
Euthyroid at baseline (n = 534)
All-cause mortality
TSH	0.64	0.43–0.95	.027	0.72	0.47–1.09	.12
FT₃	0.75	0.66–0.84	<.001	0.84	0.74–0.96	.008
FT₄	1.05	0.94–1.18	.40	1.03	0.90–1.17	.69
rT₃	1.22	1.11–1.35	<.001	1.17	1.05–1.31	.006
Cardiovascular mortality
TSH	0.74	0.44–1.24	.26	0.88	0.51–1.52	.65
FT₃	0.78	0.66–0.91	.002	0.90	0.77–1.06	.22
FT₄	1.00	0.86–1.17	.98	0.96	0.81–1.13	.61
rT₃	1.21	1.06–1.38	.006	1.10	0.95–1.28	.20

	Model 1^a			Model 2^b
	HR^c	95% CI	P-Value	HR^c	95% CI	P-Value
Full cohort (n = 643)
All-cause mortality
TSH	0.92	0.78–1.09	.32	0.87	0.71–1.07	.19
FT₃	0.81	0.73–0.91	<.001	0.91	0.81–1.01	.08
FT₄	1.09	0.99–1.21	.08	1.07	0.96–1.19	.22
rT₃	1.23	1.12–1.34	<.001	1.18	1.07–1.31	.001
Cardiovascular mortality
TSH	1.03	0.88–1.19	.74	0.96	0.74–1.25	.76
FT₃	0.85	0.74–0.97	.02	0.97	0.84–1.12	.70
FT₄	1.03	0.90–1.17	.71	0.99	0.86–1.15	.93
rT₃	1.22	1.08–1.38	.002	1.13	0.99–1.29	.07
Euthyroid at baseline (n = 534)
All-cause mortality
TSH	0.64	0.43–0.95	.027	0.72	0.47–1.09	.12
FT₃	0.75	0.66–0.84	<.001	0.84	0.74–0.96	.008
FT₄	1.05	0.94–1.18	.40	1.03	0.90–1.17	.69
rT₃	1.22	1.11–1.35	<.001	1.17	1.05–1.31	.006
Cardiovascular mortality
TSH	0.74	0.44–1.24	.26	0.88	0.51–1.52	.65
FT₃	0.78	0.66–0.91	.002	0.90	0.77–1.06	.22
FT₄	1.00	0.86–1.17	.98	0.96	0.81–1.13	.61
rT₃	1.21	1.06–1.38	.006	1.10	0.95–1.28	.20

Adjusted for age and sex

Adjusted for age, sex, education, BMI, smoking, disease count

HR per sd increase of: 3.223 mU/L TSH, 0.496 pmol/L FT₃, 2.470 pmol/L FT₄, 0.109 nmol/L rT₃.

This Feature Is Available To Subscribers Only